NTRK2

Across TCGA pan-cancer cohorts, NTRK2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NTRK2 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher NTRK2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NTRK2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where NTRK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.813	0.557	.025	5	view →
PDAC	DFS	Median	II,III,IV	0.310	0.675	.021	2	view →
LUAD	DFS	Median	All	0.662	1.000	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NTRK2–LSCC (DFS)

Open the LSCC breakdown →